1270 related articles for article (PubMed ID: 25866972)
1. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
2. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
3. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
4. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
5. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
[TBL] [Abstract][Full Text] [Related]
6. TIGIT predominantly regulates the immune response via regulatory T cells.
Kurtulus S; Sakuishi K; Ngiow SF; Joller N; Tan DJ; Teng MW; Smyth MJ; Kuchroo VK; Anderson AC
J Clin Invest; 2015 Nov; 125(11):4053-62. PubMed ID: 26413872
[TBL] [Abstract][Full Text] [Related]
7. IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.
Sun Z; Fourcade J; Pagliano O; Chauvin JM; Sander C; Kirkwood JM; Zarour HM
Cancer Res; 2015 Apr; 75(8):1635-44. PubMed ID: 25720800
[TBL] [Abstract][Full Text] [Related]
8. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
9. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.
Wang Y; Wang C; Qiu J; Qu X; Peng J; Lu C; Zhang M; Zhang M; Qi X; Li G; Hua K
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288463
[TBL] [Abstract][Full Text] [Related]
11. Perturbed CD8
Tauriainen J; Scharf L; Frederiksen J; Naji A; Ljunggren HG; Sönnerborg A; Lund O; Reyes-Terán G; Hecht FM; Deeks SG; Betts MR; Buggert M; Karlsson AC
Sci Rep; 2017 Jan; 7():40354. PubMed ID: 28084312
[TBL] [Abstract][Full Text] [Related]
12. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
[No Abstract] [Full Text] [Related]
13. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
14. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
[TBL] [Abstract][Full Text] [Related]
15. TIGIT presents earlier expression dynamic than PD-1 in activated CD8
Hu F; Wang W; Fang C; Bai C
Exp Cell Res; 2020 Nov; 396(1):112260. PubMed ID: 32890458
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Matsuzaki J; Gnjatic S; Mhawech-Fauceglia P; Beck A; Miller A; Tsuji T; Eppolito C; Qian F; Lele S; Shrikant P; Old LJ; Odunsi K
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7875-80. PubMed ID: 20385810
[TBL] [Abstract][Full Text] [Related]
17. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
18. Expansion of Tumor-Infiltrating CD8
Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
[TBL] [Abstract][Full Text] [Related]
19. Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.
Fuhrman CA; Yeh WI; Seay HR; Saikumar Lakshmi P; Chopra G; Zhang L; Perry DJ; McClymont SA; Yadav M; Lopez MC; Baker HV; Zhang Y; Li Y; Whitley M; von Schack D; Atkinson MA; Bluestone JA; Brusko TM
J Immunol; 2015 Jul; 195(1):145-55. PubMed ID: 25994968
[TBL] [Abstract][Full Text] [Related]
20. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]